NCT05067972
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: B7-H4
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with advanced/metastatic, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term
https://ClinicalTrials.gov/show/NCT05067972